Role of Thromboxane A2 in Coronary Vascular Disorders

  • Allan M. Lefer
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 46)

Abstract

Thromboxane A2 (TxA2) is a potent eicosanoid having a biological profile consistent with its being a mediator of circulatory disease states. Thus, TxA2 is a very potent vasoconstrictor. Indeed, TxA2 constricts all vascular beds in which it has been studied, and is generally regarded as the most potent endogenous vasoconstrictor known at this time (1, 2). Thromboxane A2 also is a powerful inducer of platelet aggregation and thus considered to be a very important thrombogenic substance (3). In addition to these obvious mediator actions, TxA2 also is a membrane lytic substance promoting leakiness of lysosomal and endothelial cell membranes (1, 4). These actions all complement each other in the mediation of ischemic disorders. Thus, vasoconstriction in the region around a thrombus will further obstruct flow in an artery, and endothelial cell membrane leakiness will further contribute to hypovolemia and restrict oxygen delivery to an already ischemic area.

Keywords

Ischemia Aspirin Prostaglandin Cardiol Creatine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lefer AM, Smith EF III, Araki H, Smith JB, Aharony D, Claremon DA, Magolda RL, Nicolaou KC: Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci USA (77):1706–1710, 1980.PubMedCrossRefGoogle Scholar
  2. 2.
    Ellis EF, Oelz O, Roberts LG II, Payne NA, Sweetman BJ, Nies AS, Oates JA: Coronary arterial smooth muscle contraction by a substance released from platelets: Evidence that it is thromboxane A2. Science (193):1135–1136, 1976.PubMedCrossRefGoogle Scholar
  3. 3.
    Hamberg M, Svensson J, Samuelsson B: Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA (72):2994–2998, 1975.PubMedCrossRefGoogle Scholar
  4. 4.
    Lefer AM: Eicosanoids as mediators of ischemia and shock. Fed Proc (In Press, 1984).Google Scholar
  5. 5.
    Lefer AM: Role of prostaglandins and thromboxanes in shock states. In: Altura BA, Lefer AM, Schumer W (eds.) Handbook of Shock and Trauma, Vol. 1. Raven Press, New York, 1983, pp. 355–376.Google Scholar
  6. 6.
    Smith EF III, Lefer AM, Aharony D, Smith JB, Magolda RL, Claremon D, Nicolaou KC: Carbocyclic thromboxane A2: Aggravation of myocardial ischemia by a new synthetic thromboxane A2 analog. Prostaglandins (21):443–456, 1981.PubMedCrossRefGoogle Scholar
  7. 7.
    Schrör K, Smith EF III, Bickerton M, Smith JB, Nicolaou KC, Magolda R, Lefer AM: Preservation of ischemic myocardium by pinane thromboxane A2. Am J Physiol (238):H87-H92, 1980.PubMedGoogle Scholar
  8. 8.
    Coker SJ, Parratt JR, Ledingham I McA, Zeitlin IJ: Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291:323–324, 1981.PubMedCrossRefGoogle Scholar
  9. 9.
    Coker SJ, Ledingham I McA, Parratt JR, Zeitlin IJ: Aspirin inhibits the early myocardial release of thromboxane B2 and ventricular ectopic activity following acute coronary artery occlusion in dogs. Brit J Pharmacol (72):593–595, 1981.Google Scholar
  10. 10.
    Burke SE, Antonaccio MJ, Lefer AM: Lack of thromboxane A2 involvement in the arrhythmias occurring during acute myocardial ischemia in dogs. Basic Res Cardiol (77):411–422, 1982.PubMedCrossRefGoogle Scholar
  11. 11.
    Burke SE, Lefer AM, Smith GM, Smith JB: Prevention of extension of ischemic damage following acute myocardial ischemia by dazoxiben, a new thromboxane synthetase inhibitor. Br J Clin Pharmacol (15):97S-101S, 1983.PubMedGoogle Scholar
  12. 12.
    Burke SE, Lefer DJ, Lefer AM: Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia. Arch int Pharmacodyn Therap (265):76–84, 1983.Google Scholar
  13. 13.
    Burke SE, DiCola G, Lefer AM: Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor. J Cardiovasc Pharmacol (5):842–847, 1983.PubMedCrossRefGoogle Scholar
  14. 14.
    Smith EF III, Lefer AM, Smith JB: Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Canad J Physiol Pharmacol (58):294–300, 1980.CrossRefGoogle Scholar
  15. 15.
    Lefer AM, Okamatsu S, Smith EF III, Smith JB: Beneficial effects of a new thromboxane synthetase inhibitor in arachidonate-induced sudden death. Thromb Res (23):265–273, 1981.PubMedCrossRefGoogle Scholar
  16. 16.
    Lefer AM, Müller HG, Smith JB: Pathophysiological mechanisms of sudden death induced by platelet activating factor (PAF). Brit J Pharmacol In Press, 1984.Google Scholar
  17. 17.
    Lefer AM, Burke SE, Smith JB: Role of thromboxanes and prostaglandin endoperoxides in the pathogenesis of eicosanoid induced sudden death. Thromb Res (32):311–320, 1983.PubMedCrossRefGoogle Scholar
  18. 18.
    Burke SE, Roth DM, Lefer AM: Antagonism of platelet aggregation by 13-azaprostanoic acid in acute myocardial ischemia and sudden death. Thromb Res (29):473–488, 1983.PubMedCrossRefGoogle Scholar
  19. 19.
    Brownlee M, Cahill GF: Diabetic control and vascular complications. In Paoletti RW, Gotto AM (eds.) Atherosclerosis Reviews. Raven Press, New York, 1979, pp. 29–70.Google Scholar
  20. 20.
    Palik I, Kotai MZ, Hadhazy P, Malomvolgyi M, Wagner M, Pogatsa G: Effects of prostaglandins E2, I2 and F on the tone of isolated coronary arteries from alloxan-diaoetic dogs. Prostaglandins Leuko Med (8):607–614, 1982.Google Scholar
  21. 21.
    Reibel DK, Roth DM, Lefer BL, Lefer AM: Hyperreactivity of coronary vasculature in platelet perfused hearts from diabetic rats. Am J Physiol (245):H640-H645, 1983.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1985

Authors and Affiliations

  • Allan M. Lefer

There are no affiliations available

Personalised recommendations